Q1. I am researching the usage of Pembrolizumab for the treatment of Melanoma. How many patients have you treated with Pembrolizumab in the three months from October to December 2022 for:
a. Melanoma – any stage
b. Melanoma – Stage IIb/IIc
c. Melanoma – Stage III
d. Melanoma – Metastatic
Q2. How many Stage IIb/IIc melanoma patients were on a “Watch and Wait” strategy in the three months from October to December 2022? These would be patients where a decision has been made to wait before commencing any treatment.
